Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. [electronic resource]
Producer: 20180621Description: 2288-2301 p. digitalISSN:- 1533-4406
- Aged
- Anaplastic Lymphoma Kinase
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Bevacizumab -- administration & dosage
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Female
- Genes, erbB-1
- Humans
- Immunotherapy
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis -- drug therapy
- Paclitaxel -- administration & dosage
- Receptor Protein-Tyrosine Kinases -- genetics
- Survival Analysis
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.